Comparing tolerability of olanzapine in schizophrenia and affective disorders: A meta-analysis

Medicine & Life Sciences

• Antipsychotic Agents 5%
• Bipolar and Related Disorders 10%
• Bipolar Disorder 45%
• Blood Glucose 19%
• Cardiovascular Diseases 8%
• Cholesterol 12%
• Databases 3%
• Depressive Disorder 6%
• Diabetes Complications 5%
• Diet 4%
• Duration of Therapy 5%
• Exercise 3%
• Health Care Outcome Assessment 3%
• Hypnotics and Sedatives 5%
• Incidence 11%
• Industry 5%
• Information Storage and Retrieval 5%
• LDL Cholesterol 5%
• Life Style 4%
• Logistic Models 3%
• low density lipoprotein triglyceride 6%
• MEDLINE 5%
• Mental Disorders 4%
• Meta-Analysis 48%
• Metabolic Syndrome 5%
• Mood Disorders 62%
• Morbidity 3%
• Mortality 2%
• Olanzapine 78%
• Parkinsonian Disorders 19%
• Phenotype 10%
• Psychiatry 8%
• Psychomotor Agitation 14%
• PubMed 4%
• Randomized Controlled Trials 7%
• Schizophrenia 52%
• Sex Ratio 6%
• Smoking 4%
• Tardive Dyskinesia 7%
• Therapeutics 3%
• Triglycerides 14%
• Type 2 Diabetes Mellitus 4%
• Weight Gain 21%
• Weights and Measures 3%

Chemical Compounds

• Antiparkinson Agent 9%
• Antipsychotic 8%
• Cholesterol 21%
• Disorder 55%
• Dose 4%
• Glucose 17%
• Industry 4%
• Low-Density Lipoprotein 6%
• Metabolic 23%
• Olanzapine 100%
• Sedative Agent 8%
• Triglyceride 24%
• Weight 3%
• Weight Gain 29%